John C. Plant, a director at Jabil Inc. (NYSE:JBL), recently sold a significant portion of his holdings in the company, according to a filing with the Securities and Exchange Commission.

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Navigation Menu Toggle navigation Sign in Product ...

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances ...

Pii’s addition to Jabil’s portfolio brings scientific expertise and a range of pharmaceutical development and manufacturing services. Credit: Jabil Inc./Business Wire. Jabil has acquired contract ...

abrdn plc lessened its stake in Jabil Inc. (NYSE:JBL – Free Report) by 10.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

Jabil (JBL) closed at $167.32 in the latest trading session, marking a +0.48% move from the prior day.

Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best ...

The deal complements Jabil’s specialty in injectable drug delivery systems, like those used for popular GLP-1 diabetes drugs Ozempic and Wegovy. Jabil Inc. has acquired a large pharmaceutical ...